Answers are grounded in this paper and cite their sources.
Current treatments for advanced gastric cancer are mainly palliative though the role of chemotherapy is evolving. Reference regimens vary, depending on the region and cultural preferences and in the United States, a combination of 5-fluorouracil and cisplatin is often used in untreated patients with advanced gastric cancer. There is a renewed interest in developing newer standards given the availability of novel agents including irinotecan, taxanes (paclitaxel and docetaxel), oxaliplatin and novel oral fluoropyrimidines like S-1. These have been used in the last five years either singly or in combination with promising results. We anticipate that with trials combining these agents, improved methodologies with appropriate endpoints, as well as the availability of molecular profiling techniques and a better understanding of molecular targets, we will be able to develop better treatments for patients with advanced gastric cancer.
No takes yet. Share an insight, caveat, or question.
Varadhachary et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: